Overview

An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy

Status:
Completed

Trial end date:
2019-05-27

Target enrollment:

Participant gender:

Summary

This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.

Phase:

Phase 2

Details

Lead Sponsor:

GW Research Ltd

Treatments:

Cannabidiol
Stiripentol
Valproic Acid